8-K: QT Imaging Announces FY24 Results, Projects Strong Growth for 2025 and 2026

QT Imaging reports increased revenue and gross margin for 2024, forecasts substantial revenue growth for 2025 and 2026, and highlights strategic partnerships and debt restructuring.

Summary

• QT Imaging announced its fourth quarter and full year 2024 financial results on March 31, 2025.
• The company generated approximately $5 million in revenue from twelve scanner sales in 2024, with a 54% gross margin.
• QT Imaging secured a $2.56 million PIPE investment from insiders and closed a $10.1 million term loan with Lynrock Lake.
• The company cleared all its short-term debt liabilities and entered into a manufacturing agreement with Canon Medical Systems Corporation.
• QT Imaging forecasts revenue growth to $18 million in 2025 and $27 million in 2026.
• Commercial revenue for Q4 2024 was $0.8 million, compared to $0.1 million for Q4 2023.
• Net loss for 2024 was $9.0 million, including $3.6 million of non-cash interest expense.
• Adjusted EBITDA for 2024 was $(7.3) million, compared to $(2.9) million in 2023.
• The company shipped twelve QT Breast Acoustic CTTM Scanners in 2024, compared to none in 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant revenue growth and strategic partnerships, but tempered by the net losses and delisting from Nasdaq.

Positives

• Revenue increased significantly from less than $0.1 million in 2023 to $4.9 million in 2024.
• Gross margin improved from negative in 2023 to 54% in 2024.
• The company secured a $2.56 million PIPE investment from insiders.
• QT Imaging closed a $10.1 million term loan with Lynrock Lake.
• The company cleared all its short-term debt liabilities.
• QT Imaging entered into a manufacturing agreement with Canon Medical Systems Corporation.
• The company forecasts revenue growth to $18 million in 2025 and $27 million in 2026.
• The company received a third year renewal of its five-year research grant from the National Institute of Health (NIH)/National Cancer Institute (NCI).

Negatives

• The company experienced a net loss of $9.0 million for the year ended December 31, 2024.
• Adjusted EBITDA was negative at $(7.3) million for the year ended December 31, 2024.
• Net cash used in operating activities was $10.0 million for the year ended December 31, 2024.
• The company's common stock was delisted from Nasdaq and commenced trading in the over-the-counter market.

Risks

• The company's ability to sell and deploy the QT Imaging Breast Acoustic CT Scanner is subject to risks and uncertainties.
• The company's ability to extend product offerings into new areas or products is not guaranteed.
• Unexpected occurrences could deter the full documentation and bring to market plan for products.
• Changes in demand and purchasing volume of customers could impact the company's performance.
• The company faces unpredictability of suppliers.
• The company's ability to attract and retain qualified personnel is uncertain.
• Changes in domestic and foreign business, market, financial, political, and legal conditions could affect the company.
• The company's ability to obtain and access financing in the future is not guaranteed.
• The company's ability to pay its debt obligations as they come due is subject to risk.
• The company has identified a material weakness in its internal controls over financial reporting.

Future Outlook

The company plans to deliver $18 million in revenue in 2025 (shipment of 40 scanners) and $27M in revenue in 2026 (shipment of 60 scanners).

Management Comments

• Dr. Raluca Dinu, Company's Chief Executive Officer, stated that the company has successfully turned around and is positioned for long-term growth.
• Dr. Dinu expressed confidence in the company's ability to deliver on its financial targets for 2025 and 2026.

Industry Context

QT Imaging operates in the medical device industry, specifically focusing on breast imaging systems. The company's partnerships with NXC Imaging and Canon Medical Systems Corporation are aimed at strengthening its distribution and manufacturing capabilities in the competitive breast imaging market.

Comparison to Industry Standards

• It is difficult to compare QT Imaging directly to industry standards without more specific information on its competitors and their performance.
• Companies like Hologic, GE Healthcare, and Siemens Healthineers are major players in the medical imaging market, but they offer a broader range of products and services.
• QT Imaging's focus on low-frequency sound wave technology for breast imaging differentiates it from companies that primarily use X-ray, MRI, or ultrasound technologies.
• The company's ability to achieve its revenue targets of $18 million in 2025 and $27 million in 2026 will be a key indicator of its success in the market.

Management Changes

Related Party Transactions

• The Company announced insiders PIPE investment of $2.56 Million, fully funded by the QTI Board of Directors members and Management.

Stakeholder Impact

• Shareholders may be impacted by the delisting from Nasdaq and the subsequent trading on the OTCQB Venture Market.
• Employees may be affected by the company's restructuring and focus on commercialization.
• Customers may benefit from the company's partnerships and increased manufacturing capacity.
• Suppliers may see increased demand as the company scales up its production.
• Creditors are impacted by the company's debt restructuring and new term loan.

Next Steps

• The company plans to deliver $18 million in revenue in 2025 (shipment of 40 scanners).
• The company plans to deliver $27M in revenue in 2026 (shipment of 60 scanners).
• The Company intends to apply for listing on Nasdaq if in the future it is able to qualify to list under the Nasdaqs initial listing standards.

Key Dates

Keywords

QT Imaging, Financial Results, Breast Acoustic CT Scanner, Revenue Growth, Medical Device, Lynrock Lake Term Loan, Canon Medical Systems, QTIH, OTCQB